Plain-English translation of NCT06029998 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called in men with advanced prostate cancer that has become resistant to standard hormone therapies and has a specific genetic mutation (PTEN deletion). Researchers want to see whether this medication can slow or shrink the cancer by lowering PSA levels—a marker used to track prostate cancer. The medication is given as injections under the skin over several cycles of treatment.
Standard hormone-blocking drugs stop working for some men with advanced prostate cancer, especially those whose cancer cells have lost a gene called PTEN. This trial exists to find out if this medication might help patients whose cancers have developed this genetic change and are no longer responding to other available options.
If you enroll, you would receive injections of the medication under your skin on specific days (days 1, 4, 8, and 11) in repeating 21-day cycles, with a goal of completing up to 8 cycles of treatment. The research team would monitor your PSA levels and overall health throughout the trial to see how you're responding. You would need to visit the clinic regularly for injections, blood work, and check-ins, and the study team would ask you about any side effects you experience.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States